KR100550132B1 - 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드 - Google Patents

호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드 Download PDF

Info

Publication number
KR100550132B1
KR100550132B1 KR1020007002861A KR20007002861A KR100550132B1 KR 100550132 B1 KR100550132 B1 KR 100550132B1 KR 1020007002861 A KR1020007002861 A KR 1020007002861A KR 20007002861 A KR20007002861 A KR 20007002861A KR 100550132 B1 KR100550132 B1 KR 100550132B1
Authority
KR
South Korea
Prior art keywords
delete delete
protein
rsv
modified
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007002861A
Other languages
English (en)
Korean (ko)
Other versions
KR20010030620A (ko
Inventor
핸콕제랄드이.
테비폴더블유.
Original Assignee
와이어쓰 홀딩스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 홀딩스 코포레이션 filed Critical 와이어쓰 홀딩스 코포레이션
Publication of KR20010030620A publication Critical patent/KR20010030620A/ko
Application granted granted Critical
Publication of KR100550132B1 publication Critical patent/KR100550132B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020007002861A 1997-09-19 1998-09-17 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드 Expired - Fee Related KR100550132B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5968497P 1997-09-19 1997-09-19
US60/059,684 1997-09-19
US8486398P 1998-05-08 1998-05-08
US60/084,863 1998-05-08
PCT/US1998/019656 WO1999014334A1 (en) 1997-09-19 1998-09-17 Peptides derived from the attachment (g) protein of respiratory syncytial virus

Publications (2)

Publication Number Publication Date
KR20010030620A KR20010030620A (ko) 2001-04-16
KR100550132B1 true KR100550132B1 (ko) 2006-02-08

Family

ID=26739056

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007002861A Expired - Fee Related KR100550132B1 (ko) 1997-09-19 1998-09-17 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드

Country Status (13)

Country Link
EP (1) EP1015595B1 (enExample)
JP (1) JP2001516583A (enExample)
KR (1) KR100550132B1 (enExample)
CN (1) CN1259422C (enExample)
AT (1) ATE287957T1 (enExample)
AU (1) AU751022B2 (enExample)
BR (1) BR9812240A (enExample)
CA (1) CA2302833C (enExample)
CY (1) CY1105010T1 (enExample)
DE (1) DE69828801T2 (enExample)
ES (1) ES2236946T3 (enExample)
PT (1) PT1015595E (enExample)
WO (1) WO1999014334A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1334119B2 (en) 2000-10-18 2018-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for modulating rsv infection and immunity
AUPR520201A0 (en) * 2001-05-23 2001-06-14 Commonwealth Scientific And Industrial Research Organisation Antiviral compounds
NL1019228C1 (nl) 2001-10-25 2003-04-28 Duynstee Holding B V Verbeterd gecombineerd ophang- en verlichtingssysteem voor bijvoorbeeld schilderijen e.d.
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
DE10219219A1 (de) 2002-04-29 2003-11-06 Tampoflex Gmbh Druckanlage
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
RU2006117366A (ru) 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные бензазепина в качестве ингибиторов мао-в
US7666433B2 (en) * 2004-06-30 2010-02-23 Wyeth Holdings Corporation Recombinant RSV strains with altered G protein
EP2181121A4 (en) * 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
EP2453903B1 (en) * 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
EP3956351A1 (en) * 2019-04-18 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
AU722494C (en) * 1996-06-05 2007-03-29 Commonwealth Scientific And Industrial Research Organisation Viral peptides with structural homology to protein G of respiratory syncytial virus
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide

Also Published As

Publication number Publication date
CN1259422C (zh) 2006-06-14
DE69828801D1 (de) 2005-03-03
AU9572598A (en) 1999-04-05
CA2302833C (en) 2007-05-08
JP2001516583A (ja) 2001-10-02
WO1999014334A1 (en) 1999-03-25
CN1322250A (zh) 2001-11-14
KR20010030620A (ko) 2001-04-16
BR9812240A (pt) 2000-07-18
DE69828801T2 (de) 2005-07-14
CA2302833A1 (en) 1999-03-25
PT1015595E (pt) 2005-05-31
AU751022B2 (en) 2002-08-08
ES2236946T3 (es) 2005-07-16
CY1105010T1 (el) 2010-03-03
EP1015595A1 (en) 2000-07-05
EP1015595B1 (en) 2005-01-26
ATE287957T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
US12324834B2 (en) Nucleic acid vaccine against the SARS-CoV-2 coronavirus
US20240408195A1 (en) Epstein-barr virus vaccines
EP0832253B1 (en) Nucleic acid respiratory syncytial virus vaccines
CN114096675A (zh) 冠状病毒免疫原性组合物和其用途
KR20010030620A (ko) 호흡 신시티아 바이러스의 부착 (지) 단백질에서 유도된펩티드
JPH03502687A (ja) レスピラトリイ・シンシチアル・ウイルス：ワクチンおよび診断法
JP2003180385A (ja) コロナウイルスに対するワクチン接種用組成物および方法
KR20140122258A (ko) Rsv 감염의 예방 및 치료를 위한 혼합 항원 및 dna 백신
US20160144021A1 (en) Vaccine Composition And Method Of Use
US20100068226A1 (en) Polynucleotides and Uses Thereof
US20250000968A1 (en) Sars-cov-2 spike fused to a hepatitis b surface antigen
EP1334119B2 (en) Compositions and methods for modulating rsv infection and immunity
KR20220008816A (ko) 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
CN103442729A (zh) 疟疾的治疗和预防
AU2018278927A1 (en) Methods and compositions for dengue virus vaccines
US6699478B1 (en) Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
KR20230107260A (ko) Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
US20240316183A1 (en) Sars-cov-2 subunit vaccine
BR122024015865A2 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção
BR112016007868B1 (pt) Nanopartícula, seu uso, proteína de fusão, molécula de ácido nucleico, vacina contra o vírus do epstein-barr e método para a sua produção
AU2005260580A1 (en) Recombinant rsv strains with altered g protein

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090202

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090202

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000